GLP-1 Receptor Agonists Reduce Early Postoperative Opioid Use 43% Compared to DPP-4 Inhibitors After Shoulder Surgery
Background
Patients with type 2 diabetes mellitus face an elevated risk of complications following orthopedic shoulder procedures. While both Dipeptidyl Peptidase-4 (DPP-4) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists effectively manage type 2 diabetes, their specific impacts on perioperative and long-term shoulder outcomes, particularly regarding pain management and reoperation rates, have remained largely uncharacterized. Understanding these differential effects is crucial for optimizing medication selection in this vulnerable patient population, potentially improving recovery trajectories and reducing postoperative burdens.
Study Design
This retrospective cohort study utilized the TriNetX Research Network to compare outcomes in adults (≥18 years) with type 2 diabetes who underwent orthopedic shoulder procedures. Patients were stratified based on whether they were prescribed a DPP-4 inhibitor or a GLP-1 receptor agonist. Propensity score matching (1:1) was meticulously performed, adjusting for demographics, comorbidities, and procedure type, resulting in 632 patients per cohort. Primary endpoints included rates of reoperation at one and two years postoperatively, alongside an assessment of early, prolonged, and chronic postoperative opioid use.
Results
The study found that reoperation rates at both one-year and two-year follow-up were statistically similar between patients on DPP-4 inhibitors and those on GLP-1 receptor agonists. However, a significant difference emerged in early postoperative pain management:
DPP-4 users experienced significantly higher early postoperative opioid use compared with GLP-1 users (RR: 1.754; 95% CI: 1.440-2.137; p < 0.001). This indicates that GLP-1 users had approximately 43% lower early opioid requirements. Despite this initial disparity, rates of prolonged and chronic postoperative opioid use were comparable between both cohorts. These findings suggest that while both incretin-based therapies offer similar long-term surgical outcomes, GLP-1 receptor agonists may provide an additional benefit in acute pain modulation, potentially via central pain-modulating effects.
Key Findings
- Reoperation rates at one and two years post-orthopedic shoulder surgery were similar between DPP-4 inhibitor and GLP-1 receptor agonist users.
- DPP-4 inhibitor users had significantly higher early postoperative opioid use (RR: 1.754, p < 0.001) compared to GLP-1 receptor agonist users.
- GLP-1 receptor agonist users experienced approximately 43% lower early postoperative opioid requirements.
- Prolonged and chronic postoperative opioid use rates were similar between both DPP-4 inhibitor and GLP-1 receptor agonist cohorts.
Why It Matters
This research highlights a crucial distinction for clinicians and patients with type 2 diabetes undergoing shoulder surgery: GLP-1 receptor agonists may significantly reduce immediate postoperative opioid requirements. This finding is particularly relevant given the ongoing opioid crisis and the desire to minimize opioid exposure. While both drug classes demonstrated comparable long-term surgical outcomes, the potential for GLP-1 RAs to confer additional benefits through central pain modulation could influence perioperative medication choices. For individuals managing type 2 diabetes and facing surgery, discussing GLP-1 RA options with their physician could lead to a smoother, less opioid-dependent recovery. This suggests a practical shift towards favoring GLP-1 RAs in the perioperative setting for this specific patient group, potentially improving patient experience and reducing the risk of opioid-related complications.
glp-1-agonist
dpp-4-inhibitor
type-2-diabetes
orthopedic-surgery
opioid-use
pain-management